Notes
National Health Service
Reference
PRNewswire. People with radioiodine refractory differentiated thyroid cancer (RAI-R DTC) are overlooked as Lenvima (lenvatinib) is not scheduled for evaluation by NICE or the new Cancer Drugs Fund. Internet Document : 2 Aug 2016. Available from: URL: http://www.prnewswire.co.uk/news-releases/rare-cancer-drug-which-significantly-delays-progression-of-advanced-thyroid-cancer-is-left-off-relaunched-cancer-drugs-fund-588884911.html
Rights and permissions
About this article
Cite this article
Long wait for levatinib in some UK thyroid cancer patients. PharmacoEcon Outcomes News 759, 31 (2016). https://doi.org/10.1007/s40274-016-3296-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3296-6